Table 1.
Clinical characteristics of all the study participants.
| Variable | T1D (n=90) | T2D (n=36) | HCs (n=40) |
|---|---|---|---|
| Sex (male/female) | 59/31 | 23/13 | 26/14 |
| Age (years) | 25.59 ± 11.96#### | 44.69 ± 7.82 | 28.25 ± 7.62#### |
| BMI (kg/m2) | 20.71 ± 3.17####**** | 24.09 ± 3.17 | 23.72 ± 3.04 |
| Duration (months) | 27.68 ± 30.27 | 46.39 ± 48.62 | NA |
| FBG (mmol/L) | 7.10 (5.68-10.12)**** | 8.63 (7.11-10.03)**** | 4.71 (4.34-4.97) |
| FCP (mmol/L) | 116.0 (49.08-190.5)####**** | 501.6 (359.7-660.2) | 357.1 (258.6-381.6) |
| PCP (mmol/L) | 249.9 (67.8-481.6)#### | 1175 (621.5-1501) | NA |
| HbA1c (%) | 7.87 ± 2.12**** | 8.09 ± 1.91**** | 5.27 ± 0.26 |
| TG (mmol/L) | 0.73 (0.59-1.11)####* | 1.90 (1.21-3.4)** | 1.00 (0.70-1.83) |
| TC (mmol/L) | 4.55 ± 1.10 | 4.89 ± 0.89 | 4.70 ± 1.04 |
| LDL-C (mmol/L) | 2.93 ± 0.88 | 2.90 ± 0.80* | 3.00 ± 0.93 |
| HDL-C (mmol/L) | 1.55 ± 0.40####*** | 1.18 ± 0.35 | 1.29 ± 0.28 |
| GADA | 60/90 (66.7%) | NA | NA |
| IA-2A | 55/90 (61.1%) | NA | NA |
| ZnT8A | 34/90 (37.8%) | NA | NA |
The data are expressed as the mean ± standard deviation or as the median of the 25th-75th percentile in parentheses. NA, not applicable.
##P<0.01, compared with T2D patients. #### P<0.0001, compared with T2D patients. *P<0.05, compared with HCs.
**P <0.01, compared with HCs. ****P<0.0001, compared with HCs.